Duloxetine Drug Interactions Are Issue For Yentreve, But Not For Cymbalta
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA’s neuropharm and urology review divisions hold differing opinions on duloxetine drug interactions, Cymbalta review documents indicate. Due to potential QT risk, urology division delays Yentreve approval for stress urinary incontinence; neuropharm division believes potential QT effect can be considered post-approval.